These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27557140)

  • 1. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.
    Romiti A; Roberto M; D'Antonio C; Onesti CE; Barucca V; Milano A; Gentile G; Lionetto L; Medda E; Mazzuca F; Botticelli A; Falcone R; Simmaco M; Marchetti P
    Anticancer Drugs; 2016 Nov; 27(10):1044-9. PubMed ID: 27557140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 5. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer].
    Lee J; Jeong CK; Hong SP; Chong SY; Oh D; Hwang SG; Ahn DH; Kim S; Han JH; Kim NK
    Korean J Gastroenterol; 2005 Jul; 46(1):32-8. PubMed ID: 16030402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
    Robien K; Bigler J; Yasui Y; Potter JD; Martin P; Storb R; Ulrich CM
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):973-80. PubMed ID: 16920564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
    Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion.
    Kim NK; Choi YK; Kang MS; Choi DH; Cha SH; An MO; Lee S; Jeung M; Ko JJ; Oh D
    Thromb Res; 2006; 117(6):653-8. PubMed ID: 15985285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine.
    Botticelli A; Scagnoli S; Roberto M; Lionetto L; Cerbelli B; Simmaco M; Marchetti P
    J Oncol Pharm Pract; 2020 Dec; 26(8):1836-1842. PubMed ID: 32131682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis.
    Lopomo A; Ricciardi R; De Rosa A; Guida M; Maestri M; Lucchi M; Melfi F; Mussi A; Migliore L; Coppedè F
    Gene; 2018 Feb; 642():376-380. PubMed ID: 29162511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of methylenetetrahydrofolate reductase (MTHFR 677C>T) and thymidylate synthase (TSER and TS 1494del6) polymorphisms with premature ovarian failure in Korean women.
    Rah H; Jeon YJ; Choi Y; Shim SH; Yoon TK; Choi DH; Cha SH; Kim NK
    Menopause; 2012 Nov; 19(11):1260-6. PubMed ID: 22713864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of
    Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
    Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.
    Soo RA; Syn N; Lee SC; Wang L; Lim XY; Loh M; Tan SH; Zee YK; Wong AL; Chuah B; Chan D; Lim SE; Goh BC; Soong R; Yong WP
    Sci Rep; 2016 Jun; 6():27826. PubMed ID: 27296624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.